Special Issue "Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management - Part II"
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Vascular Medicine".
Deadline for manuscript submissions: 15 June 2023 | Viewed by 100
Special Issue Editor
Interests: angiogenesis; endothelial cells; hypoxia inducible factor; β-adrenergic receptor antagonists; cancer research; von hippel-lindau; hereditary hemorrhagic telangiectasia; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Due to the impact of the Special Issue on Diagnosis and Management on Hereditary Hemorrhagic Telangiectasia, JCM decided to start a second Special Issue.
Hereditary Hemorrhagic Telangiectasia (HHT), an autosomal dominant heritable disease, leads to vascular multi-organ system and ranges from mucocutaneous telangiectases to large arteriovenous malformations. HHT has a prevalence of 1 in 5,000, becoming one of the most prevalent RDs and its diagnosis is based on the Curaçao criteria. HHT disease presents subtypes, depending on the mutations in ENG or ACVRL1/ALK1 genes, both belonging to the TGF-β/BMP9 signaling pathway, or other locations to be determined. If no diagnosis or a wrong diagnosis happens, the disease leads to a decreased life expectancy since HHT is associated with a decreased quality of life and severe complications.
This Special Issue aims (again) to highlight not only the current knowledge regarding the diagnosis and management of HHT but also the newest sequencing strategies and/or mutation hot spots. It also encourages to the presentation of international collaborative works in the diagnosis and management of the disease or related circumstances such as the pandemic year we have suffered.
All this knowledge will dramatically contribute to a better quality of life by shorting the diagnosis and further medical assistance.
Dr. Angel M. Cuesta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Activin Receptor-like Kinase 1 (ALK1/ACVRL1)
- Endoglin (ENG)
- Transforming Growth Factor Beta (TGF-β)
- Bone Morphogenetic Protein (BMP)
- SMAD4
- genotype–phenotype correlation
- transcription regulation
- biomarker
